NCT01644253 2021-05-20Phase 1b Safety and Efficacy Study of TRU-016Aptevo TherapeuticsPhase 1 Terminated87 enrolled
NCT01317901 2017-06-28A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent LymphomaAptevo TherapeuticsPhase 1 Completed12 enrolled 15 charts